Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$643.1MCash on Hand
48.9mo Cash Runway
Follow NAMS by emailGet an email when NAMS reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NAMS, unsubscribe in one click. Privacy
📣 What NAMS Says Is Next
in 2026 · “Additionally, NewAmsterdam expects to initiate a new clinical trial evaluating obicetrapib for the prevention of early Alzheimer’s disease in 2026.”
Company press release, Aug 5, 2026 · SEC filing
by year end 2026 · “The trial is expected to enroll approximately 300 patients, with topline data expected by year end 2026.”
Company press release, Aug 5, 2026 · SEC filing
during 2026 · “Upcoming Milestones and Ongoing Trials: Following the successful completion and positive topline results of the Phase 3 BROADWAY, TANDEM, and BROOKLYN trials, NewAmsterdam plans to announce additional clinical data from these trials relating to obicetrapib and the fixed-dose combination (“FDC”) of obicetrapib plus ezetimibe during 2026.”
Company press release, Aug 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 4, 2026 ·
Earnings Reported Q3 2026 revenue of $19.2 million, mostly from Menarini regulatory milestones, and R&D expenses of $39.4 million versus $31.0 million a year earlier. Cash, equivalents and securities were $643.1 million at September 30, 2026. Form 8-K · SEC filing · Press release
Nov 4, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Sep 29, 2026 ·
Clinical trial Dosed the first participant in the Phase 2b SPINOZA trial evaluating obicetrapib in preclinical Alzheimer's disease. The roughly 400-participant, 52-week study will measure change in plasma p-tau217 as its primary endpoint. Form 8-K · SEC filing · Press release
Sep 21, 2026 ·
Regulatory The European Commission granted marketing authorization for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg), the first regulatory approval of obicetrapib worldwide. Form 8-K · SEC filing
Aug 14, 2026 ·
Leadership Robert W. Gunning was appointed principal accounting officer effective August 10, 2026, succeeding Louise Kooij, whose departure takes effect August 31, 2026. He joined as Vice President, Controller, with a $375,000 base salary and a 30% target bonus. Form 8-K · SEC filing
Aug 14, 2026 ·
Leadership COO Douglas Kling resigned effective August 14, 2026, to become CEO of another clinical-stage biotech. He will serve as an advisor through May 14, 2027, for a $50,000 monthly fee, supporting the PREVAIL trial of obicetrapib. Unvested equity not tied to that service is forfeited. Form 8-K/A · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Nov 2027 · Phase 3 · Active Trial · A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque Registry primary completion date, not a results date
Mar 2028 · Phase 3 · Active Trial · A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2… Registry primary completion date, not a results date
Sep 2028 · Phase 2 · Recruiting · Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease Registry primary completion date, not a results date
Nov 2026 · Phase 3 · Active Trial · Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease Registry date passed, readout not confirmed
Nov 2026 · Phase 2 · Recruiting · Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels Registry date passed, readout not confirmed
Sep 2026 · Phase 2 · Recruiting · Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers Registry date passed, readout not confirmed
Also used in these trials (approved or third-party drugs, not NAMS's own candidates): Ezetimibe, Atorvastatin Calcium, Rosuvastatin Calcium.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
NAMS holds $643.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $39.5M/quarter from operations,
an estimated runway of 48.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:25 · Moderate
Cash runway 49 months
ATM program on file since Feb 2025 +15
Shelf registration (S-3, Feb 2025) +10
Recent financing filings on SEC EDGAR:
Feb 28, 2025 · Shelf registration with ATM program, up to $250M · S-3
Share count 119,929,998 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full NAMS picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NAMS and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.